Stay updated on RC48-ADC in HER2+ Biliary Cancer Clinical Trial
Sign up to get notified when there's something new on the RC48-ADC in HER2+ Biliary Cancer Clinical Trial page.

Latest updates to the RC48-ADC in HER2+ Biliary Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedA new revision entry (v3.3.4) has been added to the study record history, while the previous revision (v3.3.3) was removed. This is an administrative update to the history listing and does not affect study details.SummaryDifference0.1%

- Check17 days agoChange DetectedThe record history adds last known status details (sponsor, date, verification) and a Recruitment Status entry to the study record.SummaryDifference0.9%

- Check31 days agoChange DetectedA new revision entry (v3.3.3) was added to the study record history, and the HHS Vulnerability Disclosure link and the Revision: v3.3.2 entry were removed from the page footer.SummaryDifference0.2%

- Check59 days agoChange DetectedThe Record History now lists a new revision entry, v3.3.2, and removes the earlier v3.2.0 entry. This is a backend version-tracking update that does not alter study details or user-visible content.SummaryDifference0.1%

- Check67 days agoChange DetectedRemoved the top-of-page notice about government funding and operating status, which previously informed users about funding-related updates. This change eliminates contextual messaging but does not modify the study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check81 days agoChange DetectedThe updates appear to be cosmetic UI adjustments on the Record History page, such as minor formatting of the version list, with no edits to study data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to RC48-ADC in HER2+ Biliary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RC48-ADC in HER2+ Biliary Cancer Clinical Trial page.